Lilly to present Foundayo, retatrutide, eloraTZP data at EASD 2026
The company will detail new cardiometabolic findings across three programs at the European diabetes meeting.
PR
By Priya Raman · Science Reporter
Sep 15 06:45 ETSource: PR Newswire
The wire
- 01Eli Lilly said it will present new data on Foundayo, retatrutide and eloraTZP at EASD 2026.
- 02Broad readout slate covers Lilly's next-generation obesity and diabetes pipeline.
- 03Specific endpoints and results will not be public until the congress.
From the source
Read at news.google.comLilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health